Mark Sulkowski, MD

CRS:

JHU

Role:

Investigators

Position:

Site Investigator

Email:

msulkows@jhmi.edu
  • Chair, Hepatitis TSG (Dec 2016)
  • Chair, Steering Committee of Hepatitis TSG (Dec 2016)
  • SC Representative, Scientific Agenda Steering Committee (Dec 2014)
  • Member, HBV Cure Working Group of the HEP TSG (Mar 2015)
  • Co-Chair, NASH Focus Group of the ITSG/HEPTSG (April 2016)
  • Chair 5329
  • Vice-Chair, 5360
  • Co-chair 5334s
  • Investigator, 5335s

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

A5320: Viral Hepatitis C Infection Long-term Cohort Study...

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1...

Read More

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

ACTIV-2/A5401: Adaptive Platform Treatment for Outpatients...

Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More